Recursion Pharmaceuticals, INC

Recursion Pharmaceuticals announced strong pipeline execution and platform advancements in Q2 2026, highlighted by Genentech exercising an option for a neuroscience target and positive clinical updates for REC-4881 and REC-7735.

Recursion Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.

Recursion Pharmaceuticals reports Q1 2026 results with strong pipeline execution, favorable early clinical data for REC-1245, and disciplined capital management extending cash runway into early 2028.

Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman, a seasoned oncology drug development executive, as its new Chief Medical Officer, effective April 6, 2026.

Recursion Pharmaceuticals announced positive clinical validation for its AI-driven platform in FAP, achieved a fifth Sanofi milestone, and extended its cash runway into early 2028.

Recursion Pharmaceuticals presented an updated investor presentation at the JP Morgan Healthcare Conference, highlighting progress in its AI-native drug discovery platform and clinical pipeline, including positive REC-4881 FAP data.

Recursion Pharmaceuticals, Inc. reported a significant decrease in total revenue for the second quarter of 2026, alongside continued substantial operating losses, while highlighting progress in key collaborations and internal pipeline development.

Recursion Pharmaceuticals reports a decrease in revenue and operating costs for Q1 2026, with a net loss of $117.5 million, while advancing its drug discovery platform and pipeline.

Recursion Pharmaceuticals reported a significant increase in net loss for Q3 2025, driven by higher R&D expenses and strategic acquisitions, while advancing its AI-driven drug discovery pipeline.

Recursion Pharmaceuticals reported a significant increase in net loss for Q2 2025, driven by higher R&D expenses and the integration of recent acquisitions, while advancing its AI-driven drug pipeline.

Recursion Pharmaceuticals announces its Q1 2025 financial results, showcasing advancements in its pipeline and ongoing collaborations.

Recursion Pharmaceuticals announced its Q3 2024 financial results, showcasing increased revenue and advancements in its clinical programs and strategic partnerships.

Recursion Pharmaceuticals reports significant progress in 2025, achieving its first AI-enabled clinical proof of concept and advancing a diversified pipeline through its integrated AI-native drug discovery and development platform.

Recursion Pharmaceuticals highlights its AI-driven drug discovery advancements, clinical milestones, and strategic partnerships in its 2024 10-K filing, emphasizing its commitment to decoding biology to radically improve lives.

Recursion Pharmaceuticals' 10-K filing highlights its progress in TechBio, emphasizing its AI-driven drug discovery platform, clinical pipeline advancements, and strategic collaborations.

Najat Khan, CEO and President and a Director of Recursion Pharmaceuticals, Inc., reported a transaction in 80,498 shares of common stock on August 17, 2026.

David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 26,657 shares of common stock on August 17, 2026.

Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc., reported a transaction in 25,018 shares of common stock on August 17, 2026.

Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc., sold 30,000 shares of common stock on August 4, 2026 for $3.25 per share.

Blake Borgeson, a director at Recursion Pharmaceuticals, Inc., has reported the sale of 40,000 shares of Class A Common Stock.

Dar Zavain, a Director at Recursion Pharmaceuticals, received a stock grant under the company's Outside Director Compensation Policy.

Recursion Pharmaceuticals has filed a definitive proxy statement with the SEC.

Recursion Pharmaceuticals' 2025 proxy statement outlines its strategy to leverage AI and data to transform drug discovery, including a major merger with Exscientia and advancements in clinical programs.

Recursion Pharmaceuticals and Exscientia amend their transaction agreement to include the appointment of Exscientia board members to Recursion's board following the acquisition.

Recursion Pharmaceuticals will release its Q3 2024 financial results on November 6th and plans an investor update call on November 20th, following the anticipated close of its merger with Exscientia.

Recursion Pharmaceuticals is set to acquire Exscientia in an all-stock transaction aimed at combining their AI-driven drug discovery platforms.

Recursion Pharmaceuticals emphasizes the strategic rationale behind its proposed acquisition of Exscientia, focusing on the convergence of biology and chemistry expertise to enhance drug discovery.

Mubadala Investment Company affiliates have significantly reduced their beneficial ownership in Recursion Pharmaceuticals, Inc. to approximately 1.9% of outstanding shares, marking an exit for some entities.

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 6.6% of Recursion Pharmaceuticals Inc. common stock as of June 30, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.97% of Recursion Pharmaceuticals Inc. common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 26,744,129 shares, representing 5.09% of Recursion Pharmaceuticals Inc.'s common stock.

State Street Corporation has reported a beneficial ownership of 5.5% in Recursion Pharmaceuticals Inc. as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Recursion Pharmaceuticals Inc. following an internal realignment.

Baillie Gifford & Co. reported a 4.6% beneficial ownership in Recursion Pharmaceuticals Class A Common Stock as of December 31, 2025.